Ondine Biomedical Inc. (OBIMF)

Revenue by Product

Financials in millions GBX. Fiscal year is January - December.

Year Ending	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019	Dec 31, 2018	Dec 31, 2017	Dec 31, 2010
Antimicrobial Photodynamic Therapy	717.04K
Antimicrobial Photodynamic Therapy Growth	80.23%

Revenue by Geography

Financials in millions GBX. Fiscal year is January - December.

Year Ending	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019	Dec 31, 2018	Dec 31, 2017	Dec 31, 2010
Canada	669.95K
Canada Growth	80.26%
Other	47.09K
Other Growth	79.78%